Andrew J. Cutler, MD: Neuroimaging for ADHD

Researchers have been unable to leverage new technology for ADHD screening.

Screening in attention deficit/ hyperactivity disorder (ADHD) remains a challenge in the field.

While technology has improved in other fields, researchers remain unable to develop a reliable and accurate method using neuroimaging or biomarkers to detect the disorder in patients.

Because of the complexities of the brain in compared to the heart, for example, developing these techniques may prove to be allusive.

In an interview with HCPLive®, Andrew J. Cutler, MD, Clinical Professor of Psychiatry at SUNY Upstate Medical University, explained the disappointment in the inability to leverage some of the emerging technologies being utilized in other spaces to detect ADHD early in patients.

Because of this it remains unknown or doubtful whether or not diagnostic practices in ADHD will change much in the next few years.

However, Cutler said currently screening techniques, which mainly involve self-assessment and interviews with teachers and family members, are effective.

In fact, it is common to detect the disorder in 5 or 6 year old children, and possible to diagnose a child as young as 2 or 3 with ADHD.

Cutler presented multiple times during the annual Neuroscience Education Institute Max! Virtual meeting on ADHD and other psychiatric disorders.

Related Videos
Victor Kim, MD: Addressing Comorbidities and Advancing COPD Care
Cedric Rutland, MD: Exploring Immunology's Role in Molecule Development
Panagis Galiatsatos, MD: Closing the Gap in Lung Cancer Screening
Antonio Anzueto, MD: Advancing Triple-Therapy Inhalers for COPD
Panagis Galiatsatos, MD
Cedric Rutland, MD: Mechanisms Behind Immunology, Cellular Communication
Glenn S. Tillotson, PhD: Treating Immunocompromised Patients With RBX2660
© 2023 MJH Life Sciences

All rights reserved.